Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Lymphoma, Non-Hodgkin 10Lymphoma, Large B-Cell, Diffuse 5Lymphoma, B-Cell 5Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Leukemia, Lymphocytic, Chronic, B-Cell 4Lymphoma, Follicular 3Burkitt Lymphoma 3Myelodysplastic Syndromes 2Lymphoma, Mantle-Cell 2Sarcoma, Kaposi 1Myeloproliferative Disorders 1Myelodysplastic-Myeloproliferative Diseases 1Multi-centric Castleman's Disease 1Leukemia, Myeloid, Acute 1Leukemia 1Hodgkin Disease 1Castleman Disease 1Acquired Immunodeficiency Syndrome 1

Interventions

Cyclophosphamide 38fludarabine phosphate 34Peripheral Blood Stem Cell Transplantation 28Busulfan 26Tacrolimus 22Antilymphocyte Serum 22Mycophenolic Acid 21Filgrastim 20Cyclosporine 20Radiotherapy 17Methotrexate 16Melphalan 14Whole-Body Irradiation 12Etoposide 12Methylprednisolone 11Cord Blood Stem Cell Transplantation 11Cytarabine 8Sirolimus 7Alemtuzumab 7Psychiatric Rehabilitation 6Flow Cytometry 6Cyclosporins 6Thiotepa 5Rituximab 5Polymerase Chain Reaction 4Early Intervention, Educational 4sargramostim 3Immunologic Techniques 3Immunoenzyme Techniques 3Granulocyte Colony-Stimulating Factor 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelodysplastic-Myeloproliferative Diseases × tocilizumab × Lymphoid × Clear all
NCT03434730 2026-05-26

Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation

Memorial Sloan Kettering Cancer Center

Phase 2 Completed
46 enrolled 8 charts
LymphoidMyeloidOther hematologic neoplasm

Hodgkin Disease, Leukemia, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Myelodysplastic-Myeloproliferative Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡